Showing 2071-2080 of 2735 results for "".
- Candela Acquires Ellipsehttps://modernaesthetics.com/news/candela-acquires-ellipse/2472039/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Thermi Debuts Arvati Platformhttps://modernaesthetics.com/news/themi-debuts-arvati-platform/2472041/Thermi, an Almirall company, is launching Arvati, a next-generation 510K US Food and Drug Administration-cleared, true temperature-controlled radiofrequen
- Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Markethttps://modernaesthetics.com/news/cynosure-to-distribute-porter-instruments-nitrous-oxide-and-oxygen-system-in-aesthetics-market/2472047/Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument&#
- Evolus Resubmits BLA for DWP-450 Ahead of Schedulehttps://modernaesthetics.com/news/evolus-resubmits-bla-for-dwp-450-ahead-of-schedule/2472049/Evolus has resubmitted its Biologics License Application (BLA) for its lead product candidate, DWP-450 (prabotulinumtoxinA), to the FDA. The resubmission follows the receipt of a Complete Response Letter (“CRL”) from the FDA in May 2018 which necessita
- Bonti's Novel Neurotoxin Shows Promise in Early Study of Scar Reduction After Mohs Surgeryhttps://modernaesthetics.com/news/bontis-novel-neurotoxin-shows-promise-in-early-study-of-scar-reduction-after-mohs-surgery/2472052/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical
- With New Applicator, Cryolipolysis is an Option for Male Pseudogynecomastiahttps://modernaesthetics.com/news/withnew-applicator-cryolipolysis-is-an-option-for-male-pseudogynecomastia/2472059/Thanks to a conformable surface applicator, cryolipolysis can be a safe and effective way to treat male pseudogynecomastia, according to a recent
- Power of Two: AMSPA, IALA To Mergehttps://modernaesthetics.com/news/power-of-two-amspa-iala-to-merge/2472062/The American Med Spa Associatio
- RealSelf: Laser & Energy Report Identifies Key Trendshttps://modernaesthetics.com/news/realself-laser-energy-report-identifies-key-trends/2472067/Demand for fat reduction is at an all-time high, and interest in vaginal rejuvenation continues to surge. These are among key findings of the newly release RealSelf US Laser & Energy Report, released this week. First in a ne
- TempSure Vitalia from Cynosure Hits North American Markethttps://modernaesthetics.com/news/tempsure-vitalia-from-cynosure-hits-north-american-market/2472068/Hologic's Cynosure division has launched TempSure™ Vitalia in North America. TempSure Vitalia is an FDA-cleared and Health Canada-approved advanced radiofrequency treatment that delivers therapeutic heat to inter
- Alana Sine Appointed Chief Financial Officer at Merz North Americahttps://modernaesthetics.com/news/alana-sine-appointed-chief-financial-officer-at-merz-north-america/2472072/Merz North America has appointed Alana Sine to Chief Financial Officer (CFO), Merz North America. Ms. Sine has served as interim CFO since March 2018. Ms. Sine will lead the finance function for North America, overseeing financial report